© 2022 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Flash CGM Increases Time in Range for T2D Patients on Noninsulin Therapies Not at Goal HbA1c
June 10th 2022
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
Continuous Glucose Monitoring Linked to Better Glycemic Control, Reduced Hospitalizations in Study of Veterans Health Administration Data
June 8th 2022
ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.
Glycemic Variability with Tirzepatide Significantly Lower vs Degludec as Assessed by CGM
June 8th 2022
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
Poorly Controlled T2D Improves with Initiation of rtCGM in Primary Care
June 8th 2022
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date
June 7th 2022
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
Semaglutide 2.4 mg Reduces 10-year Risk of Type 2 Diabetes in Patients with Overweight, Obesity
June 7th 2022
ADA 2022: Reduction in risk of progression to type 2 diabetes of 60% was seen in STEP program clinical trial participants with overweight or obesity.
Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI
June 7th 2022
ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.
Oral Semaglutide in Real-world Study Found Highly Effective for Uncontrolled HbA1c
June 7th 2022
ADA 2022: Oral semaglutide may be particularly effective for T2D patients with HbA1c ≥9% and prescribed more frequently for these patients by primary care clinicians.
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
June 6th 2022
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
June 6th 2022
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.